Hexarelin vs Ipamorelin: GH Secretagogue Comparison

# Hexarelin vs Ipamorelin: GH Secretagogue Comparison

For Research Purposes Only -- Not Intended for Human or Animal Consumption

Introduction

Hexarelin (His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2) and Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) are both synthetic hexapeptide GH secretagogues that act through the ghrelin receptor (GHS-R1a). They were developed during the same era of GHRP research and share structural similarities, but differ in potency, selectivity, and -- most notably -- in Hexarelin's documented cardiac effects that appear to be independent of GHS-R1a.

Potency Comparison

Hexarelin is generally considered more potent than Ipamorelin on a molar basis for GH release. Studies comparing the two compounds in rats have demonstrated that Hexarelin produces higher peak GH levels at equivalent doses. However, this potency advantage comes with a less selective pharmacological profile.

Selectivity Differences

Ipamorelin: As reviewed in the Ipamorelin vs GHRP-6 comparison, Ipamorelin is highly selective for GHS-R1a with minimal effects on cortisol, prolactin, or ACTH. This selectivity makes it the preferred GHRP for most research applications.

Hexarelin: Less selective than Ipamorelin, producing dose-dependent cortisol and prolactin elevations similar to GHRP-6. At doses producing maximal GH release, Hexarelin produces significant HPA axis activation that limits its utility in studies where cortisol confounding is a concern.

Hexarelin's Cardiac Effects: A Unique Property

The most pharmacologically distinctive feature of Hexarelin is its documented cardiac effects that appear to be mediated through a receptor other than GHS-R1a. Muccioli et al. (2004) identified a specific Hexarelin binding site in cardiac tissue that is distinct from GHS-R1a and is not activated by other GHRPs including Ipamorelin and GHRP-6.

This cardiac receptor mediates protective effects in ischemia-reperfusion injury models. Broglio et al. (1999) demonstrated that Hexarelin administration improved cardiac function and reduced infarct size in rat models of myocardial ischemia -- effects that were not replicated by Ipamorelin or GHRP-6 at equivalent doses.

The cardiac receptor for Hexarelin has been proposed to be CD36, a scavenger receptor expressed on cardiomyocytes, though this identification remains somewhat controversial in the literature.

Desensitization Profiles

A significant practical difference between Hexarelin and Ipamorelin is their desensitization profiles with repeated administration.

Hexarelin: Produces significant GHS-R1a desensitization with repeated daily administration. Studies in humans have demonstrated that daily Hexarelin administration leads to progressive attenuation of the GH response over 2-4 weeks of continuous use.

Ipamorelin: Shows less pronounced desensitization with repeated administration, though some attenuation of the GH response has been documented with very frequent dosing. The more favorable desensitization profile of Ipamorelin is one of the reasons it has become the preferred GHRP for research protocols.

Research Application Implications

The choice between Hexarelin and Ipamorelin depends on the research question:

- For cardiac protection research: Hexarelin's unique cardiac receptor activity makes it the preferred compound - For GH/IGF-1 research: Ipamorelin's cleaner selectivity profile and better desensitization profile make it preferable - For potency-focused studies: Hexarelin's higher potency may be advantageous at lower doses

References

1. Muccioli, G., et al. (2004). Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. European Journal of Pharmacology, 498(1-3), 27-35.
2. Broglio, F., et al. (1999). The endocrine and non-endocrine activities of GH secretagogues. International Journal of Obesity, 23(Suppl 1), S19-S27.
3. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.